At a glance
- Originator Bristol-Myers Squibb
- Class Antiglaucomas
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 15 Mar 2001 No-Development-Reported for Glaucoma in USA (Ophthalmic)
- 23 Jul 1997 New profile
- 23 Jul 1997 Preclinical development for Glaucoma in USA (Ophthalmic)